Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract
associated with high rates of malignant transformation. Most GISTs present …

Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the
gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in …

Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …

Background The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery
needs to be estimated when considering adjuvant systemic therapy. We assessed …

Gastrointestinal stromal tumors (GISTs) have emerged from being poorly defined, treatment-
resistant tumors to a well-recognized, well-understood, and treatable tumor entity within only …

Background Laparoscopic resection of gastric GISTs appears technically feasible and
associated with favorable outcomes. Tumor size however frequently plays a role in surgical …

BACKGROUND: Approval of imatinib for adjuvant treatment of gastrointestinal stromal
tumours (GIST) raised discussion about accuracy of prognostic factors in GIST and the …

Gastrointestinal stromal tumors (GISTs) are rare life-threatening forms of cancer that may
arise anywhere in the GI tract. Herein, we aimed to review the literature to describe the …

Following the successful introduction of the receptor tyrosine kinase inhibitors (TKI) as the
mainstay for the treatment of advanced and metastatic gastrointestinal stromal tumor (GIST) …

Background Patients with gastrointestinal stromal tumour (GIST) are often followed up after
surgery with longitudinally repeated imaging examinations to detect recurrence early …